Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo gel Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

NCT00720590
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Atazanavir, Lopinavir/ritonavir, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
CD07805/47, CD07805/47 placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 28, 2026, 2:15 AM EDT
Withdrawn Phase 2 Interventional

RCT of SPG Blocks for Post-dural Headache

NCT03560349
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Lidocaine HCl Gel 2%, placebo gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

NCT01585831
View directory record Official record
Conditions
Klinefelter Syndrome, XXY Syndrome
Interventions
Testosterone gel 1%, Placebo gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

NCT02515305
View directory record Official record
Conditions
Acne
Interventions
Clindamycin and Benzoyl Peroxide Gel (combination), Clindamycin and Benzoyl Peroxide Gel (Reference) (combination), Placebo gel (combination)
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 28, 2026, 2:15 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
View directory record Official record
Conditions
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 2:15 AM EDT
Terminated Phase 1Phase 2 Interventional

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

NCT04409145
View directory record Official record
Conditions
Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions
VT30
Drug
Lead sponsor
Venthera, Inc., a BridgeBio company
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 28, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional Results available

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

NCT02194621
View directory record Official record
Conditions
Oral Bacteria Levels in the Mouth
Interventions
Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
22 Years to 58 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

NCT03927716
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 28, 2026, 2:15 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 28, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00438321
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Zoladex, Testosterone gel, Anastrozole Pill, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 28, 2026, 2:15 AM EDT
Terminated Not applicable Interventional

Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes

NCT02212652
View directory record Official record
Conditions
Vitamin D Deficiency, Vitamin D Insufficiency
Interventions
Vitamin D, Placebo, Standard of Care
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

NCT02462954
View directory record Official record
Conditions
Contraception
Interventions
ContraGel, HEC Universal Placebo gel
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

NCT03362957
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Geniculate Artery Embolization, Sham Procedure
Device · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Results available

Benzocaine Gel Toothache Dose-Response Study

NCT00474175
View directory record Official record
Conditions
Toothache
Interventions
Placebo gel, benzocaine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
12 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow

NCT03068377
View directory record Official record
Conditions
Ocular Blood Flow
Interventions
Experimental, Placebo
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 28, 2026, 2:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 28, 2026, 2:15 AM EDT
Not listed Phase 1 Interventional

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

NCT01843686
View directory record Official record
Conditions
Acute Burns
Interventions
Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care
Device · Other
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 28, 2026, 2:15 AM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Sep 28, 2026, 2:15 AM EDT